Crawley Clinical Commissioning Group (CCCG) and GlaxoSmithKline UK (GSK) Osteoporosis

All parties have committed resources to support this project, which will run from November 2012 – November 2013

The purpose of this Joint Working project is to improve the quality and productivity in the management of patients with osteoporosis within practices in the CCCG and publish as a best practice case study.

The approach will cover:

  • Evaluate the effectiveness of the current primary care (FLS) by retrospectively comparing outcomes since the service introduction
  • Publish evaluation of primary care FLS as an example of best approach
  • Development of suitable templates which can be used to collect key audit parameters to measure success and efficiency of a primary care based FLS
  • FLS team to use monthly templates reports to support restructure of current FLS protocols to drive improved efficiencies
  • Develop reports to utilise risk stratification tool to screen high risk population groups

Benefits of the project will be to:

  • The Patient
  • Increase quality of care closer to home
  • Improved continuity of care with the FLS
  • High risk patients identified and receive appropriate treatment
  • Increased patients reviews aiming to reduce hospital admissions
  • Better experience of the healthcare system

The NHS

  • Higher quality, more consistent care achieved more rapidly
  • Better health outcomes, use of resources, greater value for money, lower costs
  • More people treated appropriately (e.g. in line with national guidelines)
  • Lower costs of hospital admissions
  • Support towards achievement of performance target

GSK

  • Increased acknowledgement and understanding of the role of GSK in supporting clinical commissioning.
  • This project is intended to benefit patients by creating more opportunities for the appropriate use of medicines, including GSK’s medicines in suitable patients in line with local guidelines.
  • To document how joint working between GSK and CCCG has improved Osteoporosis patient management.

For Further Information please contact:

GSK Customer Contact Centre 0800 221 441

UK/PPM/0155b/11